Project

Back to overview

Swiss SOLIDARITY: An international public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients

English title Swiss SOLIDARITY: An international public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients
Applicant Manuel Oriol
Number 196910
Funding scheme Research Infrastructure
Research institution Service des Maladies Infectieuses Département de Médecine Interne CHUV
Institution of higher education University of Lausanne - LA
Main discipline Internal Medicine
Start/End 01.04.2020 - 31.03.2023
Approved amount 1'600'000.00
Show all

Keywords (1)

Covid-19

Lay Summary (French)

Lead
L’infection à coronavirus SARS-CoV-2, nommée COVID-19, est la pandémie la plus importante du XXIème siècle, ayant une mortalité estimée à centaines de milliers de personnes. A ce jour, aucun traitement n’a montré son efficacité contre le COVID-19.
Lay summary

Objectifs visés par le projet au début de la recherche et résultats obtenus à la fin du projet

L’étude SOLIDARITY est un essai clinique international sponsorisé par l’OMS qui vise à évaluer l’efficacité de quatre traitements pour lutter contre le COVID-19. Les patients seront randomisés et recevront soit l’hydroxychloroquine (un traitement pour la malaria), le lopinavir/ritonavir (un médicament utilisé pour traiter le VIH) associé ou non à l’interféron-béta (un traitement utilisé pour traiter la sclérose en plaques) ou le remdesivir (un traitement antiviral utilisé contre le virus Ebola).  Ces traitements seront comparés à un groupe de patients qui recevront la prise en charge habituelle, sans traitement.

Plusieurs dizaines de pays participent à cette étude, qui a pour objectif d’inclure rapidement des milliers de patients dans le monde afin de trouver le meilleur traitement pour lutter contre le COVID-19.

Contexte scientifique et social du projet de recherche

La pandémie de SARS-CoV-2 met actuellement en danger nos systèmes de santé. La découverte d’un traitement efficace contre le COVID-19 qui améliore le pronostic de la maladie pourrait donc avoir un impact majeur sur l’utilisation des ressources de santé, et par conséquent, pour la société en général.

Direct link to Lay Summary Last update: 13.04.2020

Responsible applicant and co-applicants

Project partner

Publications

Publication
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
(2021), Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results, in New England Journal of Medicine, 384(6), 497-511.

Scientific events

Active participation

Title Type of contribution Title of article or contribution Date Place Persons involved
Annual meeting Society of Thrombosis and Hemostasis Research Talk given at a conference Evidence-based approaches against Covid-19: what we have learnt from clinical trials 26.02.2021 Lausanne, Switzerland Manuel Oriol;
COVID- 19 – Role Model for Innovations in Therapy and Prevention Talk given at a conference Clinical Aspects of COVID-19 10.09.2020 Basel, Switzerland Manuel Oriol;


Knowledge transfer events

Active participation

Title Type of contribution Date Place Persons involved
SÉMINAIRE-SANTÉ « La science en période de crise ». From hydroxychloroquine to dexamethasone Talk 17.11.2020 Online, Switzerland Manuel Oriol;


Abstract

WHO SOLIDARITY trialThere are currently no available vaccines or treatments for COVID-19. Although there have been some suggestions for untested treatments that could be added to the usual care in hospitals, none is known to help. The World Health Organization (WHO) is, therefore, organizing a study in many countries in which some of these untested treatments are compared with each other, to discover whether any do help. The study treatments are remdesivir, chloroquine or hydroxychloroquine, lopinavir plus ritonavir, and interferon-beta. Some are given as daily pills, and some as daily injections.Patients invited to join the study will be those who are admitted to a collaborating hospital. Patients diagnosed with COVID-19 and who have consented to be part of the study will be randomly allocated to receive either local standard care alone or local standard care and one of a list of study drugs. During the study, some treatments may get removed from this list, and others may be added to it. Each patient will only receive one of the treatments. The patients will be followed up for the entire length of their hospital stay. Death from any cause will be recorded and this will be the main result used to determine whether a drug is effective. Length of hospital stay and time to first receiving ventilation (or intensive care) will also be recorded and used to determine the drug's effectiveness.The study is conducted between March 2020 and March 2021.
-